NRTIs

NRTIs

Abbreviation for nucleoside reverse transcriptase inhibitors.
References in periodicals archive ?
There are no clinically significant pharmacokinetic interactions between nucleoside reverse transcriptase inhibitors (NRTIs) and rifampicin-based TB treatment.
Patients should have been exposed to at least two ARV, including: nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
The older nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine and stavudine remain first-line therapy in our and other resource-limited settings.
Primary drug resistance has been reported for all three main classes of antiretroviral drugs: NRTIs, NNRTIs and PIs, and also for the fusion inhibitor, enfuvirtide (T20).
The NNRTI-based regimens typically contain one NNRTI and two nucleoside reverse transcriptase inhibitors (NRTIs).
After 24 weeks, the combination of Invirase, Agenerase, and Norvir plus nucleoside reverse transcriptase inhibitors (NRTIs or "nukes") decreased viral load and increased T cell count.
Study DPC 083-203, a phase II comparison of 100 and 200 mg once-daily DPC 083 and 2 NRTIs in patients failing a NNRTI containing regimen.
(NASDAQ: GILD) today presented findings from two Phase 3 trials--a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo(s)tide or non-nucleo(s)tide reverse transcriptase inhibitors (NRTIs or NNRTIs).
(NASDAQ: GILD) has presented findings from two Phase 3 trials a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo(s)tide or non-nucleo(s)tide reverse transcriptase inhibitors (NRTIs or NNRTIs), the company said.
In the ATLAS study, 616 participants taking two nucleoside reverse transcriptase inhibitors (NRTIs) and an integrase inhibitor, a non-NRTI, or a protease inhibitor, were randomized 1:1 to continue their regimen (CART arm) or switch to CAB/RPV, following a 4-week safety monitoring period of oral CAB/RPV After 48 weeks, 1.6% in the CAB/RPV arm and L0% in the CART arm had HIV-1 RNA greater than or equal to 50 copies/mL, which met the prespecified noninferiority margin.
In these studies, DTG + 3TC demonstrated non-inferiority based on plasma HIV-1 RNA <50 copies per milliliter (c/mL), a standard measure of HIV-1 control, at Week 48 when compared to a three-drug regimen of DTG and two nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in treatment-naive, HIV-1 infected adults.
ATLAS 48-week efficacy and safety results: The global, pivotal, phase III ATLAS study met its primary endpoint, with cabotegravir and rilpivirine demonstrating non-inferiority to an oral three-drug regimen of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent, as measured by the proportion of participants with plasma HIV-1 RNA ?50 copies per millilitre (c/mL) using the FDA Snapshot algorithm at Week 48 (cabotegravir + rilpivirine: 5/308 1.6% , current antiretroviral therapy CAR : 3/308 1.0% , adjusted difference: 0.6%, 95% confidence interval CI : -1.2, 2.5).